title: Etanercept-induced lupus accompanied by hemophagocytic syndrome.
abstract: Hemophagocytic syndrome (HPS) is a severe, potentially life-threatening disorder characterized by an excessive activation of macrophages, such as may occur in the setting of lupus. A 62-year-old Japanese woman treated with etanercept for rheumatoid arthritis developed persistent fever, cytopenia, coagulopathy, and hyperferritinemia. Simultaneously, lupus-like features including pleuritis, hypocomplementemia, and positive autoantibodies were observed. She was diagnosed with HPS related to etanercept-induced lupus, and underwent immunosuppressive therapy with successful recovery. To our knowledge, this is the first case of etanercept-induced lupus accompanied by HPS. This case suggests that HPS should be considered as a complication during TNF-α inhibitor therapy.
authors: Division of Rheumatology, Department of Internal Medicine, Kanazawa University Graduate School of Medicine, Japan.
authors: Daisuke
authors: D
authors: Araki
authors: Hiroshi
authors: H
authors: Fujii
authors: Masami
authors: M
authors: Matsumura
authors: Masakazu
authors: M
authors: Yamagishi
authors: Akihiro
authors: A
authors: Yachie
authors: Mitsuhiro
authors: M
authors: Kawano
mesh_terms: D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D008178:Lupus Erythematosus, Cutaneous / Q000139:chemically induced* / Q000150:complications / Q000175:diagnosis*; D051359:Lymphohistiocytosis, Hemophagocytic / Q000139:chemically induced* / Q000150:complications / Q000175:diagnosis*; D018124:Receptors, Tumor Necrosis Factor; D013577:Syndrome
chemical_list: D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept